<DOC>
	<DOC>NCT02026063</DOC>
	<brief_summary>The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.</brief_summary>
	<brief_title>Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<criteria>Ongoing participation in a Phase 2 (LX1606.1202CS, LX1606.1203CS) or Phase 3 (LX1606.1301CS, LX1606.1303CS) study Patients of childbearing potential must agree to use an adequate method of contraception (defined as having a failure rate of &lt;1% per year) during the study and for 12 weeks after the Followup visit. Ability and willingness to provide written informed consent Major protocol violations or tolerability concerns in a Phase 2 (eg, LX1606.1202CS, LX1606.1203CS) or Phase 3 (eg, LX1606.1301CS, LX1606.1303CS) study Positive pregnancy test Presence of any clinically significant findings at entry for medical history, laboratory values, or physical examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>